102nd Annual Meeting of the American Association for Cancer Research

March 30, 2011

COLUMBUS, Ohio – Cancer researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are available for outside comment on research presented during the 102nd Annual Meeting of the American Association for Cancer Research (AACR) April 2-6 in Orlando, Fla.

  • Dr. Michael Caligiuri, director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, will chair the “How to get your research published” session at 1 p.m. April 2. Caligiuri, who is also president of the Association of American Cancer Institutes, received a prestigious MERIT Award from the National Cancer Institute for his extensive research focusing on manipulating the immune system to prevent and treat cancer. His areas of interest include natural killer cell biology and the molecular biology of acute myeloid leukemia.
  • Dr. Tong Chen, assistant professor, division of medical oncology in the department of internal medicine and a member of the Molecular Carcinogenesis and Chemoprevention Program, specializing in molecular carcinogenesis, bionutrition, translational chemoprevention and dietary prevention research. As part of the AACR press briefing at 8 a.m. April 6, she will present research findings on a study conducted in China in which patients with precancerous esophageal lesions were successfully treated with freeze-dried strawberries.
  • Dr. Ted Teknos, director of the division of head and neck oncologic surgery and a member of the Experimental Therapeutics program. His research interests in head and neck cancer include angiogenesis; refinements in micro-vascular reconstructive surgery; development of novel therapeutics for disease treatment; identification of serum and tissue tumor markers; and overcoming chemo-resistance.
  • Gustavo Leone, associate director of basic research and a member of the Molecular Biology and Cancer Genetics program. His research focuses on understanding the control of gene expression as it relates to cellular proliferation, DNA replication, differentiation, developmental regulation and the molecular basis of cancer.
  • Dr. Charles Shapiro, director of breast medical oncology and a member of the Cancer Control program. His research interests include novel therapies and side effects of treatment for breast cancer.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.

###

Eileen Scahill
Medical Center Public Affairs and Media Relations
614-293-3737
Eileen.Scahill@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...

Read More

Individualizing Treatments for Multiple Myeloma

This week on Toward a Cancer-Free World, Dr. Craig Hofmeister shares how using an actual virus to help treat certain blood cancer patients may just get us even closer to a cancer-free world.

Read More

Generating New Hope Through Pelotonia-Funded Research

Pelotonia funds support cancer drug development projects at Ohio State. Here’s a brief look at a basic-science study of a targeted agent that may improve cancer-killing virus therapy, and two clinical...

Read More